# Array BioPharma (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/array-biopharma-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 57 |
| Citations | 157,532 |
| City | Boulder |
| Country | US |
| Description | Array BioPharma (United States) is a research organisation in Boulder, US. OpenAlex records 559 works and 157,532 citations for it. 223 researchers list it as their most recent affiliation. |
| Homepage | http://www.arraybiopharma.com/ |
| OpenAlex ID | https://openalex.org/I4210101899 |
| Region | Colorado |
| Researchers | 223 |
| ROR ID | https://ror.org/018axtd57 |
| Type | company |
| Works | 559 |

## University papers

- [Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-in-patients-with-previously-treated-non-small-cell/)
- [Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-metastatic-nonsquamous-nsclc/)
- [Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/)
- [Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial](https://scholariq.org/papers/atezolizumab-plus-bevacizumab-and-chemotherapy-in-non-small-cell-lung-cancer/)
- [Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)](https://scholariq.org/papers/phase-ii-trial-of-atezolizumab-as-first-line-or-subsequent-therapy-for-patients/)
- [Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)](https://scholariq.org/papers/differential-regulation-of-pd-l1-expression-by-immune-and-tumor-cells-in-nsclc/)

## University top topics

Showing 8 of 25.

- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Computational Drug Discovery Methods](https://scholariq.org/topics/computational-drug-discovery-methods/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Protein Kinase Regulation and GTPase Signaling](https://scholariq.org/topics/protein-kinase-regulation-and-gtpase-signaling/)
- [Chemical Synthesis and Analysis](https://scholariq.org/topics/chemical-synthesis-and-analysis/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.